FDA Grants Fast Track Status to Aegle Therapeutics’ AGLE-102 for the Treatment of Dystrophic Epidermolysis Bullosa
- Thursday, October 1, 2020, 7:06
- Finance
- Add a comment
BOSTON and MIAMI, Oct. 1, 2020 /PRNewswire/ — Aegle Therapeutics Corporation today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AGLE-102™ for the treatment of patients with dystrophic epidermolysis bullosa (“DEB”), a rare genetic pediatric…
About the Author
adminasapcorp has written 39089 stories on this site.